Skip to Main Content

Author Details

Thomas O'Hare
Huntsman Cancer Institute, University of Utah
1991
96
38
PMIDPaper TitleJournal TitlePublished Year
33412552Femoral Heads from Total Hip Arthroplasty as a Source of Adult Hematopoietic Cells.Acta Haematol2021
34504101TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth.Nat Commun2021
34027418SIRT5 IS A DRUGGABLE METABOLIC VULNERABILITY IN ACUTE MYELOID LEUKEMIA.Blood Cancer Discov2021
32409689Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms.Leukemia2020
30563936Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.Clin Cancer Res2019
31697804JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.Blood2019
31648319The transcriptome of CMML monocytes is highly inflammatory and reflects leukemia-specific and age-related alterations.Blood Adv2019
31493432BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia.Exp Hematol2019
31543464Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.Cancer Cell2019
31540978ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?Clin Cancer Res2019
30776234Identification and Characterization of AES-135, a Hydroxamic Acid-Based HDAC Inhibitor That Prolongs Survival in an Orthotopic Mouse Model of Pancreatic Cancer.J Med Chem2019
29284681A novel <i>AGGF1-PDGFRb</i> fusion in pediatric T-cell acute lymphoblastic leukemia.Haematologica2018
29588547Ongoing clonal evolution in chronic myelomonocytic leukemia on hypomethylating agents: a computational perspective.Leukemia2018
29749399Autocrine Tnf signaling favors malignant cells in myelofibrosis in a Tnfr2-dependent fashion.Leukemia2018
29707154Similar expression profiles in CD34<sup>+</sup> cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib.Oncotarget2018
28819281Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.Leukemia2017
28465516Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.Leukemia2017
28673390Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.Hematol Oncol Clin North Am2017
28852963Minimal Residual Disease Eradication in CML: Does It Really Matter?Curr Hematol Malig Rep2017
27028877Disarming an Electrophilic Warhead: Retaining Potency in Tyrosine Kinase Inhibitor (TKI)-Resistant CML Lines While Circumventing Pharmacokinetic Liabilities.ChemMedChem2016
26673800A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.Clin Cancer Res2016
26648538Age-related mutations and chronic myelomonocytic leukemia.Leukemia2016
26582647Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.Leukemia2016
27669408Sensitivity Analysis of the NPM-ALK Signalling Network Reveals Important Pathways for Anaplastic Large Cell Lymphoma Combination Therapy.PLoS One2016
27742672A Decade of Nilotinib and Dasatinib: From In Vitro Studies to First-Line Tyrosine Kinase Inhibitors.Cancer Res2016
27480386Rapid conversion of chronic myeloid leukemia to chronic myelomonocytic leukemia in a patient on imatinib therapy.Leukemia2016
27320899Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting.Sci Rep2016
27044711A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.Leukemia2016
25134459Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.Leukemia2015
26372962Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.Proc Natl Acad Sci U S A2015
26202934β-Catenin is required for intrinsic but not extrinsic BCR-ABL1 kinase-independent resistance to tyrosine kinase inhibitors in chronic myeloid leukemia.Leukemia2015
25912019Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.Exp Hematol2015
25700679Chronic myeloid leukemia: advances in understanding disease biology and mechanisms of resistance to tyrosine kinase inhibitors.Curr Hematol Malig Rep2015
25676420Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1.Leukemia2015
25721898A coiled-coil mimetic intercepts BCR-ABL1 dimerization in native and kinase-mutant chronic myeloid leukemia.Leukemia2015
25573989shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.Blood2015
25132497BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.Cancer Cell2014
27175272STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia.Leuk Suppl2014
25293778BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.Blood2014
23087056Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.Cancer Res2013
24062017Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia.Blood2013
23887971KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.Cancer Res2013
23904234What challenges remain in chronic myeloid leukemia research?Haematologica2013
23934763Kinase inhibitor therapy in CML: it's what's inside that counts.Oncotarget2013
23448894New concepts for CML clonality.Oncotarget2013
23576564Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.Cancer Res2013
23223358BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.Blood2013
22094585Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors.Leukemia2012
23190221Ponatinib in refractory Philadelphia chromosome-positive leukemias.N Engl J Med2012
22825216Pushing the limits of targeted therapy in chronic myeloid leukaemia.Nat Rev Cancer2012
  • 1 - 50 of 96

Recommended Authors

Haijiao Zhang
Oregon Health & Science University, Knight Cancer Institute
Career Start Year 2017
Number of shared co-authors 26
Jessica Leonard
Oregon Health & Science University
Career Start Year 2015
Number of shared co-authors 25
Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
Career Start Year 2011
Number of shared co-authors 25
Amanda L Christie
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 4
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Catherine C Smith
University of California San Francisco
Career Start Year 2009
Number of shared co-authors 7
Elisabeth A Lasater
University of California san francisco
Career Start Year 2008
Number of shared co-authors 1
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Career Start Year 2007
Number of shared co-authors 1
Yana Pikman
Dana Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 3
Ronan Swords
Oregon Health and Science University
Career Start Year 2004
Number of shared co-authors 27
Tara L Lin
University of Kansas Medical Center
Career Start Year 2004
Number of shared co-authors 22
Vivian G Oehler
Fred Hutchinson Cancer Center.
Career Start Year 2003
Number of shared co-authors 26
Oliver Hantschel
Institute of Physiological Chemistry, University of Marburg 35032 Marburg Germany .
Career Start Year 2003
Number of shared co-authors 14
Giovanni Roti
University of Parma
Career Start Year 2003
Number of shared co-authors 1
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 7
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Career Start Year 1997
Number of shared co-authors 11
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 5
Changchun Deng
Center for Lymphoid Malignancies, Columbia University Medical Center
Career Start Year 1997
Number of shared co-authors 0
Nathanael S Gray
Harvard Medical School
Career Start Year 1996
Number of shared co-authors 10
Kimberly Stegmaier
Dana-Farber Cancer Institute
Career Start Year 1995
Number of shared co-authors 5
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 5
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 11
Mark J Levis
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Career Start Year 1992
Number of shared co-authors 3
Jerald P Radich
Fred Hutchinson Cancer Center
Career Start Year 1989
Number of shared co-authors 31
Aaron D Schimmer
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 3
Daniel J DeAngelo
Dana-Farber Cancer Institute
Career Start Year 1989
Number of shared co-authors 18
Richard M Stone
Dana Farber Cancer Institute
Career Start Year 1986
Number of shared co-authors 21
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Career Start Year 1986
Number of shared co-authors 10
Marcela Gronda
Princess Margaret Cancer Centre
Career Start Year 1985
Number of shared co-authors 2
Junia V Melo
University of Adelaide
Career Start Year 1984
Number of shared co-authors 17

Collaborators

Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 70
Brian J Druker
Oregon Health & Science University
Co-authored papers 44
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 30
Anthony D Pomicter
Huntsman Cancer Institute, University of Utah
Co-authored papers 25
Anna M Eiring
Texas Tech University Health Sciences Center at El Paso
Co-authored papers 20
Matthew S Zabriskie
University of Utah
Co-authored papers 19
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Co-authored papers 16
Jamshid S Khorashad
Institute of Cancer Research
Co-authored papers 15
Dongqing Yan
Inner Mongolia University
Co-authored papers 13
Srinivas K Tantravahi
Huntsman Cancer Institute at the University of Utah.
Co-authored papers 10
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 10
Phillip M Clair
Huntsman Cancer Institute, The University of Utah
Co-authored papers 8
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 8
Anna Senina
Huntsman Cancer Institute, The University of Utah
Co-authored papers 7
Stephanie G Willis
OHSU Cancer Institute
Co-authored papers 6
Eric P Stoffregen
Lewis-Clark State College
Co-authored papers 6
Hein Than
Singapore General Hospital
Co-authored papers 5
Thoralf Lange
Hospital Weissenfels
Co-authored papers 5
Kara Johnson
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 5
Hannah M Redwine
Huntsman Cancer Institute, The University of Utah
Co-authored papers 4
Jonathan M Ahmann
Huntsman Cancer Institute, The University of Utah
Co-authored papers 4
Jorge Cortes
Georgia Cancer Center
Co-authored papers 4
Ryan J Mackenzie
Oregon Health & Science University, USA [2] Knight Cancer Institute
Co-authored papers 3
Amber D Bowler
Huntsman Cancer Institute, The University of Utah
Co-authored papers 3
Richard D Press
Oregon Health and Science University
Co-authored papers 3
Jennifer L Snead
University of New Mexico Health Sciences Center
Co-authored papers 3
Riccardo Baron
Co-authored papers 3
Anca Franzini
University of Utah
Co-authored papers 3
Dorian LaTocha
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Jason Gotlib
Stanford University School of Medicine
Co-authored papers 3
Release 1.2